Laden.... Wacht alsjeblieft even.
Bedrijfsprofiel
OSE Immunotherapeutics develops first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). The Company’s current well-balanced first-in-class clinical pipeline includes:
- Tedopi® (lung cancer vaccine): positive Phase 3 results in NSCLC. Other Phase 2 trials of Tedopi® in combination are ongoing in solid tumors;
- OSE-279 (anti-PD1): Phase 1/2 positive results in solid tumors;
- OSE-127/Lusvertikimab (humanized monoclonal antibody antagonist of IL-7 receptor): Phase 2 in Ulcerative Colitis. Preclinical research in leukemia;
- FR-104/VEL-101 (anti-CD28 mAb): partnership with Veloxis in transplantation; Phase 1/2 in renal transplant (CHU Nantes);
- BI 765063/BI 770371 (anti-SIRPα mAb): partnership with Boehringer Ingelheim in advanced solid tumors;
- OSE-230 (ChemR23 agonist mAb): partnership with AbbVie in chronic inflammation.
- Pro-resolutive mAb platform focused on targeting and advancing inflammation resolution in I&I;
- Myeloid Checkpoint platform focused on optimizing the therapeutic potential of myeloid cells in IO;
- Cytokine platform focused on leveraging the Cis-Delivery of cytokine in IO and I&I.
Bron:
Cofisem
-
laatste update:
03 Apr 2025
Bestuurders
| Chief Executive Officer | Nicolas Poirier | ||||
| Administrative & Finance Director | Anne-Laure Autret-Cornet | ||||
| Director of Development | Sonya Montgomery | ||||
| Head of Investor Relations | Fiona Olivier | ||||
| Bron: Cofisem - laatste update: 03 Apr 2025 | |||||
Kerncijfers
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 69.877 | 2.227 | 18.302 | 26.306 | 10.418 |
| Income from ordinary activities | 83.435 | 2.227 | 18.302 | 26.306 | 10.432 |
| Operating income | 43.735 | -22.986 | -18.476 | -16.625 | -18.989 |
| Cost of financial indebtedness net | 3.903 | 1.860 | 1.357 | 829 | 261 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | 37.445 | -23.003 | -17.760 | -16.850 | -16.555 |
| Net income (Group share) | 37.445 | -23.003 | -17.760 | -16.850 | -16.555 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Bron: Cofisem - laatste update: 03 Apr 2025 | |||||
Adres
OSE Immunotherapeutics
22 Boulevard Benoni Goullin
FR-44200
Nantes
France
Telefoonnummer:
+33 (0)2 28 29 10 10
Bron:
Cofisem
-
laatste update:
03 Apr 2025
Contact
Nicolas Poirier
Telefoonnummer: 0228291010
Bron: OSE Immunotherapeutics - laatste update: 03 Apr 2025